TN2016000170A1 - Salts of 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)- 4-(trifluormethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carboxylic acid. - Google Patents
Salts of 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)- 4-(trifluormethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carboxylic acid.Info
- Publication number
- TN2016000170A1 TN2016000170A1 TN2016000170A TN2016000170A TN2016000170A1 TN 2016000170 A1 TN2016000170 A1 TN 2016000170A1 TN 2016000170 A TN2016000170 A TN 2016000170A TN 2016000170 A TN2016000170 A TN 2016000170A TN 2016000170 A1 TN2016000170 A1 TN 2016000170A1
- Authority
- TN
- Tunisia
- Prior art keywords
- dihydro
- salts
- tetrahydropyrimidin
- trifluormethyl
- benzoxazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13192177 | 2013-11-08 | ||
| PCT/EP2014/073801 WO2015067652A1 (de) | 2013-11-08 | 2014-11-05 | Salze von 1 -(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluormethyl)-2,3-dihydro-1h-inden-1 -yl]-1,2,3,4-tetrahydropyrimidin-5-carbonsäure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2016000170A1 true TN2016000170A1 (en) | 2017-10-06 |
Family
ID=49552231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TN2016000170A TN2016000170A1 (en) | 2013-11-08 | 2014-11-05 | Salts of 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)- 4-(trifluormethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carboxylic acid. |
Country Status (32)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3338780A1 (de) | 2016-12-20 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind |
| CA3061444A1 (en) * | 2017-04-27 | 2018-11-01 | Bayer Aktiengesellschaft | Selective adrenoreceptor .alpha.2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad) |
| WO2022135502A1 (zh) * | 2020-12-25 | 2022-06-30 | 广东东阳光药业有限公司 | 多取代的尿嘧啶衍生物及其用途 |
| TW202404601A (zh) * | 2022-04-05 | 2024-02-01 | 加拿大商索科普拉健康與人類科學兩合公司 | 用於選擇性消退血栓性或血栓栓塞性疾病中血栓的凝乳酶抑制劑 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002032881A1 (en) * | 2000-10-19 | 2002-04-25 | Nippon Kayaku Kabushiki Kaisha | Novel remedies or preventives for angiostenosis |
| AT511788A1 (de) | 2011-07-29 | 2013-02-15 | Georg Dr Gaul | Vorrichtung zur vorgebbaren anordnung eines stents |
| CA2866184A1 (en) * | 2012-03-05 | 2013-09-12 | Gratuk Technologies Pty Ltd | Dietary supplement |
| UA112897C2 (uk) * | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань |
| CA2929763A1 (en) * | 2013-11-08 | 2015-05-14 | Bayer Pharma Aktiengesellschaft | Substituted uracils as chymase inhibitors |
-
2014
- 2014-11-05 LT LTEP14793565.4T patent/LT3066097T/lt unknown
- 2014-11-05 AU AU2014345599A patent/AU2014345599B2/en active Active
- 2014-11-05 UA UAA201606202A patent/UA117686C2/uk unknown
- 2014-11-05 EP EP14793565.4A patent/EP3066097B1/de active Active
- 2014-11-05 NO NO14793565A patent/NO3066097T3/no unknown
- 2014-11-05 BR BR112016010253A patent/BR112016010253A8/pt not_active Application Discontinuation
- 2014-11-05 ME MEP-2017-249A patent/ME02907B/me unknown
- 2014-11-05 AP AP2016009181A patent/AP2016009181A0/en unknown
- 2014-11-05 CA CA2929780A patent/CA2929780C/en active Active
- 2014-11-05 JP JP2016551038A patent/JP6446051B2/ja active Active
- 2014-11-05 SI SI201430450T patent/SI3066097T1/sl unknown
- 2014-11-05 HR HRP20171603TT patent/HRP20171603T1/hr unknown
- 2014-11-05 RS RS20171063A patent/RS56509B1/sr unknown
- 2014-11-05 HU HUE14793565A patent/HUE035021T2/en unknown
- 2014-11-05 ES ES14793565.4T patent/ES2645480T3/es active Active
- 2014-11-05 MX MX2016005971A patent/MX366848B/es active IP Right Grant
- 2014-11-05 WO PCT/EP2014/073801 patent/WO2015067652A1/de not_active Ceased
- 2014-11-05 PL PL14793565T patent/PL3066097T3/pl unknown
- 2014-11-05 CN CN201480057947.4A patent/CN105658647B/zh active Active
- 2014-11-05 KR KR1020167011771A patent/KR102351418B1/ko active Active
- 2014-11-05 DK DK14793565.4T patent/DK3066097T3/da active
- 2014-11-05 US US15/035,165 patent/US9926305B2/en active Active
- 2014-11-05 EA EA201600381A patent/EA033132B1/ru not_active IP Right Cessation
- 2014-11-05 TN TN2016000170A patent/TN2016000170A1/en unknown
- 2014-11-05 PT PT147935654T patent/PT3066097T/pt unknown
- 2014-11-05 MY MYPI2016701615A patent/MY190108A/en unknown
- 2014-11-05 MA MA39020A patent/MA39020A1/fr unknown
-
2016
- 2016-05-01 IL IL24540716A patent/IL245407B/en active IP Right Grant
- 2016-05-06 CL CL2016001096A patent/CL2016001096A1/es unknown
- 2016-05-06 PH PH12016500853A patent/PH12016500853B1/en unknown
- 2016-05-08 SA SA516371082A patent/SA516371082B1/ar unknown
-
2017
- 2017-10-25 CY CY20171101110T patent/CY1119520T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201592200A1 (ru) | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b | |
| EA030383B9 (ru) | Бициклически замещённые урацилы, способы их получения, их применение, лекарственное средство и способ лечения с их применением | |
| NZ710111A (en) | Quinoline and quinoxaline amides as modulators of sodium channels | |
| PH12014500758A1 (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases | |
| BR112014028042A2 (pt) | inibidores de nampt | |
| PH12013500644A1 (en) | Co-crystals and salts of ccr3-inhibitors | |
| GEP20186880B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| EA201400165A1 (ru) | Частицы на основе полиакрилата, которые содержат активное соединение | |
| CY1125224T1 (el) | Κρυσταλλικες μορφες 1-(3-τριτ-βουτυλο-1-ρ- τολυλο-1η-πυραζολ-5-υλο)-3-(5-φθορο-2-(1-(2- υδροξυαιθυλ)-ινδαζολ-5-υλοξυ)βενζυλ)ουριας υδροχλωρικη | |
| EA201492081A1 (ru) | (r)-нифурател, его применение в лечении инфекций и синтез (r)- и (s)-нифуратела | |
| PH12016500853A1 (en) | Salts of 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)- 4-(trifluormethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carboxylic acid | |
| EA201490045A1 (ru) | Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении | |
| AU2019268209A1 (en) | Compounds for the treatment of seizures and other central nervous system disorders and conditions | |
| ECSP13013043A (es) | Composición oral líquida que comprende sodio divalproex y proceso para preparar la misma | |
| MX2015006807A (es) | Metodo de preparacion de formas cristalinas de la 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1-oxidopiridin-4-il)-5-metox ipiridin-2-carboxamida y sus formas cristalinas. | |
| TH1601002185A (th) | เกลือแบบใหม่ของ 1-(3-เมธิล-2-ออกโซ-2,3-ไดไฮโดร-1,3-เบนซอกซาโซล-6-อิล)-2,4- ไดออกโซ-3-[(1r)-4-(ไตรฟลูออโรเมธิล)-2,3-ไดไฮโดร-1h-อินดิน-1-อิล]-1,2,3,4- เตตระไฮโดรไพริมิดีน-5-คาร์บอกซิลิกแอซิดและการใช้เกลือดังกล่าว | |
| MA39756A (fr) | Nouveau sel de l'ivabradine et son procédé de préparation | |
| TN2013000150A1 (en) | Co-crystals and salts of ccr3-inhibitors | |
| PL410369A1 (pl) | Nowe pochodne peptydowe, sposób ich otrzymywania, kompozycja farmaceutyczna, kompozycja dezynfekująca oraz zastosowanie i zestaw | |
| EA201790231A1 (ru) | Профилактическое или терапевтическое средство для лечения болезней заднего сегмента глаза | |
| EA201990656A1 (ru) | Пирролопиримидиновые соединения, используемые в качестве агониста tlr7 | |
| MX2012013055A (es) | Un procedimiento mejorado para purificar el complejo de cloruro de benzalconio-dialil oxido de disulfuro modificado y usos. | |
| UA103803C2 (en) | Use of 1-methoxycarbonylmethyl-7-bromo-5-phenyl-3-arylamino-1,2-dihydro-3h-1,4-benzodiazepine-ones as analgetic agents |